The study demonstrated that CD226 exhibits significant tumor type specificity: Elevated expression is observed in esophageal carcinoma, clear cell renal cell carcinoma, and stomach adenocarcinoma, while lower expression is observed in bladder cancer, chromophobe renal cell carcinoma, thyroid carcinoma, lung squamous cell carcinoma, and HCC [221]. This evidence concerns the gene CD226 and hepatocellular carcinoma.